Advertisement

Topics

Expanded label boosts AstraZeneca and Merck's Lynparza

05:38 EDT 18 Aug 2017 | BioPharmaDive

Securing a broader indication for earlier treatment of ovarian cancer should help Lynparza fend off competition from rival PARP inhibitors.

Original Article: Expanded label boosts AstraZeneca and Merck's Lynparza

NEXT ARTICLE

More From BioPortfolio on "Expanded label boosts AstraZeneca and Merck's Lynparza"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...